-
公开(公告)号：NO20062552L
公开(公告)日：2006-06-02
申请号：NO20062552
申请日：2006-06-02
Applicant: BAXTER INT
Inventor： WERLING JANE , RABINOW BARRETT E , CHAUBAL MAHESH
IPC: A61K9/14 , A61K9/10 , A61K9/127 , A61K9/16 , A61K31/12 , A61K31/337 , A61K31/495 , A61K31/496 , A61K31/55 , A61K31/573
Abstract: The present invention is concerned with the formation of submicron particles of an antineoplastic agent, particularly paclitaxel, by precipitating the antineoplastic agent in an aqueous medium to form a pre-suspension followed by homogenization. Surfactants with phospholipids conjugated with a water soluble or hydrophilic polymer such as PEG are used as coating for the particles. The particles produced generally have an average particle size of less than about 1000 nm and are not rapidly soluble.
-
公开(公告)号：AU2005255039A1
公开(公告)日：2005-12-29
申请号：AU2005255039
申请日：2005-06-08
Applicant: BAXTER HEALTHCARE SA , BAXTER INT
Inventor： KIPP JAMES E , RABINOW BARRETT E
Abstract: The present invention is concerned with a method of preparing and delivering small particles of a pharmaceutically active material to a mammalian subject for treating diseases or disorders. A preferred embodiment entails: (i) the collection of tissue cells from an animal donor, (ii) selective or non-selective growth of these cells in a cell culture medium to which is added solid particles of a therapeutically active compound, mostly free of a drug carrier (about 10% or less, by weight), and having an average particle size of less than about 100 microns, (iii) contacting the cells in the cell culture medium with the solid particles of therapeutically active compound causing the particles to be taken up by the cells into either the intracellular compartment of the cultured cells, attachment of the active compound as particles to the periphery of such cells, or a combination of intracellular uptake and attachment to the cell surface, (iv) optionally, isolation and/or resuspension of the cells prepared in steps i through iii, (v) administering the cells to the mammalian subject. The pharmaceutically active material can be administered intravenously, intramuscularly, subcutaneously, intradermally, intra-articularly, intrathecally, epidurally, intracerebrally, via buccal route, rectally, topically, transdermally, orally, intranasally, via pulmonary route, intraperitoneally, or combinations thereof. After administration, the loaded cells transport the pharmaceutical composition as particles.
-
公开(公告)号：CA2554246A1
公开(公告)日：2005-08-11
申请号：CA2554246
申请日：2005-01-21
Applicant: BAXTER INT , BAXTER HEALTHCARE SA
Inventor： KIPP JAMES E , RABINOW BARRETT E , CHAUBAL MAHESH V , WERLING JANE
IPC: A61K9/10 , A61K9/14 , A61K9/51 , A61K31/00 , A61K31/551 , A61K31/7072 , A61K31/7076
Abstract: The present invention provides compositions comprising dispersions of anti- retroviral agents and methods of manufacture. The nanosuspensions are made b y the process of microprecipitation and energy addition. Preferably, the nanosuspensions are made by the tandem process of microprecipitation- homogenization.
-
公开(公告)号：CA2540695A1
公开(公告)日：2004-12-29
申请号：CA2540695
申请日：2004-06-15
Applicant: BAXTER INT
Inventor： RABINOW BARRETT E , GENDELMAN HOWARD E , KIPP JAMES E
Abstract: The present invention is concerned with delivering a pharmaceutical composition to the brain of a mammalian subject for treating brain diseases or disorders. The process includes the steps of: (i) providing a dispersion of the pharmaceutical composition as particles having an average particle size of from about 150 nm to about 100 microns, and (ii) administering the dispersion to the mammalian subject for delivery to the brain of a portion of the pharmaceutical composition by cells capable of reaching the brain. The dispersion of the pharmaceutical composition as particles, for example, can be phagocytized or adsorbed by the cells prior or subsequent to administration into the mammalian subject. The dispersion of the pharmaceutical composition can be administered to the central nervous system or the vascular system. After administration, the loaded cells transport the pharmaceutical composition as particles into the brain.
-
公开(公告)号：AU2004234003A1
公开(公告)日：2004-11-11
申请号：AU2004234003
申请日：2004-04-29
Applicant: BAXTER INT
Inventor： RABINOW BARRETT E , REBBECK CHRISTINE L , KIPP JAMES E , SUN CHONG-SON , WONG JOSEPH CHUNG TAK , DOTY MARK J , PAPADOPOULOS PAVLOS , WHITE RANDY
IPC: A61K9/50 , A61K9/51 , A61K31/496 , A61K9/14
Abstract: The present invention relates to compositions of submicron- to micron-size particles of antimicrobial agents. More particularly the invention relates to a composition of an antimicrobial agent that renders the agent potent against organisms normally considered to be resistant to the agent. The composition comprises an aqueous suspension of submicron-tomicron-size particles containing the agent coated with at least one surfactant selected from the group consisting of: ionic surfactants, non-ionic surfactants, biologically derived surfactants, and amino acids and their derivatives. The particles have a volume-weighted mean particle size of less than 5 µm as measured by laser diffractonetry.
-
Patent Agency Ranking
公开(公告)号：AU774259B2
公开(公告)日：2004-06-24
申请号：AU4046300
申请日：2000-03-29
Applicant: BAXTER INT
Inventor： PEJAVER SATISH K , MOTHERAM RAJESHWAR , RABINOW BARRETT E , ROSA JOSBEN C DELA
Abstract: Formulations of intravenous anesthetic propofol emulsions are provided which contain sufficiently low concentrations of soybean oil to produce a stable emulsion and simultaneously provide reduced nutrients, which inhibit microbial growth thereby providing protection against accidental microbial contamination during long-term IV infusions. In addition to the inhibition of microbial growth due to a reduction of nutrients, the formulation exhibits unanticipated additional microbial inhibition due to an increased availability of propofol. The low concentration of soybean oil also provides a formulation that reduces the chances of fat overload when administered over an extended period of time to chronically ill patients.
-
公开(公告)号：BR0009541A
公开(公告)日：2002-01-02
申请号：BR0009541
申请日：2000-03-29
Applicant: BAXTER INT
Inventor： PEJAVER SATISH K , MOTHERAM RAJESHWAR , RABINOW BARRETT E , ROSA JOSBEN C DELA
Abstract: Formulations of intravenous anesthetic propofol emulsions are provided which contain sufficiently low concentrations of soybean oil to produce a stable emulsion and simultaneously provide reduced nutrients, which inhibit microbial growth thereby providing protection against accidental microbial contamination during long-term IV infusions. In addition to the inhibition of microbial growth due to a reduction of nutrients, the formulation exhibits unanticipated additional microbial inhibition due to an increased availability of propofol. The low concentration of soybean oil also provides a formulation that reduces the chances of fat overload when administered over an extended period of time to chronically ill patients.
-
28.发明专利
公开(公告)号：BRPI0414321B1
公开(公告)日：2015-05-26
申请号：BRPI0414321
申请日：2004-09-22
Applicant: BAXTER INT , BAXTER HEALTHCARE SA
Inventor： RODRIGUEZ ALFREDO , RABINOW BARRETT E , DOTY MARK J , KONKEL JAMIE
-
公开(公告)号：DK1682116T3
公开(公告)日：2012-09-03
申请号：DK04810266
申请日：2004-11-03
Applicant: BAXTER INT
Inventor： CHAUBAL MAHESH , WERLING JANE , RABINOW BARRETT E
IPC: A61K31/337 , A61K9/10 , A61K9/127 , A61K9/133 , A61K9/14 , A61K9/16 , A61K31/12 , A61K31/495 , A61K31/496 , A61K31/55 , A61K31/573
-
公开(公告)号：MX2010012451A
公开(公告)日：2010-12-07
申请号：MX2010012451
申请日：2009-05-08
Applicant: BAXTER INT
Inventor： KIPP JAMES E , RABINOW BARRETT E , WONG JOSEPH C T , NAIR LAKSHMY , MILLER REAGAN
Abstract: Se proporcionan formulaciones farmacéuticas estables y métodos para elaborarlas. En una modalidad general, la presente descripción proporciona un método para elaborar una formulación farmacéutica estable que comprende agregar uno o más aditivos de vitrificación a una solución farmacéutica acuosa para elevar la temperatura de transición al vidrio de la solución farmacéutica acuosa. La solución farmacéutica acuosa puede ser enfriada a una temperatura de aproximadamente -50°C hasta aproximadamente -10°C. El aditivo de vitrificación mejora la formación de un sólido de vidrio o amorfo de la solución farmacéutica acuosa en temperaturas criogénicas (-50°C a - 10°C), y la formulación farmacéutica puede ser descongelada a una forma líquida y administrada a un sujeto mamífero.
-
-
-
-
-
-
-
-
-
Search Results
57
records
(took 0.023 seconds)
